


The claimed invention is:

1. A compound of formula (I):



- 5 including a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein:

- R^1 is (C_1-C_{10}) alkyl, (C_3-C_{10}) cycloalkyl $(CH_2)_t-$, (C_6-C_{10}) aryl $(CH_2)_t-$, or (5-10 membered heterocycle) $(CH_2)_t-$, wherein said R^1 is optionally substituted with at least one moiety selected from the group consisting of (C_1-C_6) alkyl, halo, hydroxy, (C_1-C_6) alkoxy, halo (C_1-C_6) alkoxy, oxo, and amino;

t is an integer from 0 to 5;

- R^3 is (5-10 membered heteroaryl) $(CH_2)_s-$, (5-10 membered heterocycle) $(CH_2)_s-$, wherein said R^3 is optionally substituted with at least one moiety selected from the group consisting of (C_1-C_6) alkyl, halo, hydroxy, (C_1-C_6) alkoxy, halo (C_1-C_6) alkoxy, oxo, and amino; and

s is an integer from 0 to 5.

2. A compound of claim 1, wherein:
 R^3 is a (2-pyridinyl) $(CH_2)_s-$, (3-pyridinyl) $(CH_2)_s-$ or (4-pyridinyl) $(CH_2)_s-$;
t is an integer from 0-4; and
s is an integer from 1-5.

3. A compound of claim 1, wherein R^1 is (C_1-C_{10}) alkyl.
4. A compound of claim 1, wherein R^1 is (C_3-C_{10}) cycloalkyl $(CH_2)_t-$.
5. A compound of claim 1, wherein R^1 is (C_6-C_{10}) aryl $(CH_2)_t-$.
6. A compound of claim 5 wherein:

R^3 is a (2-pyridinyl)(CH₂)_s -, (3-pyridinyl)(CH₂)_s - or (4-pyridinyl)(CH₂)_s -;
t is an integer from 0-4; and
s is an integer from 1-5.


- 5 7. A compound of claim 6, wherein:
t is an integer from 0-3; and
s is an integer from 1-3.

8. A compound of claim 1, wherein R^1 is (5-10 membered heterocycle)(CH₂)_t -.
- 10

9. A compound of claim 8 wherein:
 R^3 is a (2-pyridinyl)(CH₂)_s -, (3-pyridinyl)(CH₂)_s - or (4-pyridinyl)(CH₂)_s -;
t is an integer from 0-4; and
s is an integer from 1-5.
- 15

10. A compound of claim 9, wherein:
t is an integer from 0-3; and
s is an integer from 1-3.

- 20 11. A compound of formula (II):



- including a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof,
25 wherein:

R^1 is C₁-C₁₀ alkyl, (C₃-C₁₀ cycloalkyl)(CH₂)_t -, (C₆-C₁₀ aryl)(CH₂)_t -, or (5-10 membered heterocycle)(CH₂)_t -, wherein said R^1 is optionally substituted with at least one moiety selected from the group consisting of (C₁-C₆)alkyl, halo, hydroxy, (C₁-C₆)alkoxy, halo(C₁-C₆)alkoxy, oxo, and amino;

t is an integer from 0 to 4;

R⁴ is H or (C₁-C₁₀)alkyl;

each R⁵ is independently H, (C₁-C₁₀)alkyl, (C₂-C₁₀)alkenyl,

(C₂-C₁₀)alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR⁶, -
5 C(O)R⁶, -C(O)OR⁶, -NR⁷C(O)OR⁶, -OC(O)R⁶, -NR⁷SO₂R⁶, -SO₂NR⁶R⁷, -NR⁷C(O)R⁶,
-C(O)NR⁶R⁷, -NR⁶R⁷, -S(O)_jR⁸, -SO₃H, -NR⁶(CR⁷R⁸)_pOR⁷, -(CH₂)_p(C₆-C₁₀ aryl),
-SO₂(CH₂)_p(C₆-C₁₀)aryl, -S(CH₂)_p(C₆-C₁₀)aryl, -O(CH₂)_p(C₆-C₁₀)aryl, -(CH₂)_p(5-10
membered heterocyclic), and -(CR⁷R⁸)_mOR⁷;

m is an integer from 1 to 5;

10 p is an integer from 0 to 5;

j is an integer from 0 to 2;

each R⁶ is independently selected from H, (C₁-C₁₀)alkyl,

(C₆-C₁₀)aryl(CH₂)_k, and (5-10 membered heterocyclic)(CH₂)_k;

k is an integer from 0 to 5;

15 each R⁷ and R⁸ is independently H or (C₁-C₆)alkyl; and

n is an integer from 1 to 4.

12. A compound of claim 11 selected from the group consisting of:

20 5-[3-(2-Cyclohex-1-enyl-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;

5-[3-(2,5-Dimethyl-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;

25 5-[3-(3,5-Dimethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;

5-[3-(2-Ethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;

5-{3-[2-(2-Ethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-
4-carboxylic acid amide;

30 5-{3-[2-(3,4-Dimethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-
isothiazole-4-carboxylic acid amide;

5-(3-Phenethyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid
amide;

- 5-{3-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(4-Ethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5 5-{3-[2-(4-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(3-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 10 5-{3-[2-(3-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(4-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(3-Bromo-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 15 5-{3-[2-(4-Bromo-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(2-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(3-Chloro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 20 5-{3-[2-(2-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(3-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 25 5-{3-[2-(4-Fluoro-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(4-Ethoxy-3-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(3-Ethoxy-4-methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;
- 30 5-{3-[2-(2,5-Dimethoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid amide;

- 5-{3-[2-(3-Methoxy-phenyl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-
isothiazole-4-carboxylic acid amide;
- 5-{3-[2-(2-Difluoromethoxy-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-
4-carboxylic acid amide;
- 5 5-{3-[2,6-Dimethoxy-benzyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-{3-[2,5-Dichloro-benzyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-{3-[3-Morpholin-4-yl-propyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
10 carboxylic acid amide;
- 5-{3-[2-Morpholin-4-yl-ethyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-{3-[2-Diethylamino-ethyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 15 5-{3-[3-Dimethylamino-propyl]-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-{3-[2-(1-Methyl-pyrrolidin-2-yl)-ethyl]-ureido}-3-(pyridin-3-ylmethoxy)-
isothiazole-4-carboxylic acid amide;
- 5-{3-[3-(2-Methyl-piperidin-1-yl)-propyl]-ureido}-3-(pyridin-3-ylmethoxy)-
20 isothiazole-4-carboxylic acid amide;
- (R),(R)-5-[3-(2-Hydroxy-cycloheptylmethyl)-ureido]-3-(pyridin-3-ylmethoxy)-
isothiazole-4-carboxylic acid amide;
- (R),(R)-5-[3-(2-Hydroxy-cyclooctylmethyl)-ureido]-3-(pyridin-3-ylmethoxy)-
isothiazole-4-carboxylic acid amide;
- 25 5-[3-(2-Hydroxy-ethyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-[3-(2-Hydroxy-butyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-{3-[3-(2-Oxo-pyrrolidin-1-yl)-propyl]-ureido}-3-(pyridin-3-ylmethoxy)-
30 isothiazole-4-carboxylic acid amide;
- 5-[3-(3-Imidazol-1-yl-propyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;

- 5-(3-Benzyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid
amide;
- 5-[3-(2,5-Difluoro-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5 3-(1-Pyridin-3-yl-ethoxy)-5-(3-pyridin-2-ylmethyl-ureido)-isothiazole-4-
carboxylic acid amide;
- 5-[3-(2,6-Dimethoxy-benzyl)-ureido]-3-(1-pyridin-3-yl-ethoxy)-isothiazole-4-
carboxylic acid amide;
- 10 5-(3-Cyclopropylmethyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide;
- 5-(3-Methyl-ureido)-3-(pyridin-3-ylmethoxy)-isothiazole-4-carboxylic acid
amide;
- 5-(3-Methyl-ureido)-3-(1-pyridin-3-yl-ethoxy)-isothiazole-4-carboxylic acid
amide; and
- 15 5-[3-(3,5-Dichloro-benzyl)-ureido]-3-(pyridin-3-ylmethoxy)-isothiazole-4-
carboxylic acid amide.

13. A pharmaceutical composition comprising a compound of any one of
claims 1-12 and a pharmaceutically acceptable carrier.
- 20 14. A method of treating a TGF-related disease state in a mammal comprising
the step of administering to the mammal suffering from the TGF-related disease
state a therapeutically effective amount of a compound of any one of claims 1-12.
- 25 15. A method of claim 8, wherein said TGF-related disease state is selected
from the group consisting of hyperproliferative disorders and fibrotic diseases.